We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Settles With States Over Deceptive Marketing
British drugmaker GlaxoSmithKline has agreed to pay $105 million to 44 states and the District of Columbia to settle allegations it engaged in deceptive marketing and sales practices on its asthma drug Advair Diskus and antidepressants Wellbutrin and Paxil.